ArticleJournal of cosmetic dermatology2026
VYC-17.5L is Safe and Effective in Improving Skin Quality and Volume Deficit of Hands: Results From an 18-Month Open-Label Study.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VYC-17.5L is Safe and Effective in Improving Skin Quality and Volume Deficit of Hands: Results From an 18-Month Open-Label Study.Journal of cosmetic dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHands undergo age-related changes in volume and skin quality. This 18-month exploratory study evaluated safety and effectiveness of VYC-17.5 L for hand rejuvenation.
methodsParticipants (≥ 35 years) with moderate-to-extreme Allergan Hand Volume Deficit Scale (AHVDS) scores received VYC-17.5L in both hands on day 1, with optional touch-up on day 30. Effectiveness was assessed by AHVDS responder rate (≥ 1-grade improvement from baseline per hand) at months 1, 3 (primary effectiveness timepoint), and at 3-month intervals through month 18; investigator- and participant-Global Aesthetic Improvement Scale (GAIS); hand Self-Perception of Age (SPA); and skin quality measurements. Safety was evaluated throughout.
resultsSeventy-five participants (94.7% female; mean age, 53.89 years) had both hands injected with VYC-17.5L (median, 2.0 mL/hand), and 60.0% of hands received touch-up (median, 1.0 mL/hand). The primary endpoint was met: 100.0% of hands were AHVDS responders at month 3. The 100% response rate was maintained through month 6, and the majority of participants (> 65%) were responders through month 18. Most hands (≥ 85%) improved on investigator- and participant-GAIS through month 12. SPA improved by 5 to 6 years. Significant skin quality improvements persisted to 12 months. Twenty-two (29.3%) participants experienced treatment-related adverse events; most were mild or moderate in severity with a mean duration of 45.1 days, and none led to study discontinuation.
conclusionVYC-17.5L is an effective treatment for improving hand volume deficit, with aesthetic benefits lasting 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.